Research graph
References from Plasma interleukin-6 levels and treatment responses to antipsychotics in schizophrenia: Focus on clozapine treatment. Local targets link to admitted publications; unresolved targets remain external evidence.
High mobility group protein 1 and Dickkopf-related protein 1 in schizophrenia and treatment-resistant schizophrenia: associations with interleukin-6, symptom domains, and neurocognitive impairments
10.1093/schbul/sbaa136 · 2021 · External reference
Molecular underpinning of treatment-resistant schizophrenia: a putative different neurobiology from treatment-responsive schizophrenia
10.3390/ijms26178598 · 2025 · External reference
Interleukin-6 in schizophrenia—is there a therapeutic relevance?
10.3389/fpsyt.2017.00221 · 2017 · External reference
Acute variations of cytokine levels after antipsychotic treatment in drug-naïve subjects with a first-episode psychosis: a meta-analysis
10.1016/j.neubiorev.2017.03.003 · 2017 · External reference
The relationship between serum cytokine levels and degree of psychosis in patients with schizophrenia
10.1016/j.psychres.2018.07.041 · 2018 · External reference
Evidence for cytokine dysregulation in schizophrenia spectrum disorders: a comparison of cerebrospinal fluid and blood samples
10.1016/j.psychres.2024.115871 · 2024 · External reference
Clozapine: why is it so uniquely effective in the treatment of a range of neuropsychiatric disorders?
10.3390/biom11071030 · 2021 · External reference
A randomized, double-blind, placebo-controlled clinical trial of Tocilizumab, an interleukin-6 receptor antibody, for residual symptoms in schizophrenia
10.1038/npp.2017.258 · 2018 · External reference
Clozapine prevents poly (I:C) induced inflammation by modulating NLRP3 pathway in microglial cells
10.3390/cells9030577 · 2020 · External reference
Alteration patterns of peripheral concentrations of cytokines and associated inflammatory proteins in acute and chronic stages of schizophrenia: a systematic review and network meta-analysis
10.1016/s2215-0366(23)00025-1 · 2023 · External reference
Sex differences in the association of treatment-resistant schizophrenia and serum interleukin-6 levels
10.1186/s12888-023-04952-0 · 2023 · External reference
Clozapine protects dopaminergic neurons from inflammation-induced damage by inhibiting microglial overactivation
10.1007/s11481-011-9309-0 · 2012 · External reference
Current topics in neuroleptic-induced extrapyramidal symptoms in Japan
10.2302/kjm.45.95 · 1996 · External reference
Peripheral biomarkers of treatment-resistant schizophrenia: genetic, inflammation and stress perspectives
10.3389/fphar.2022.1005702 · 2022 · External reference
The association between interleukin family and diabetes mellitus and its complications: an overview of systematic reviews and meta-analyses
10.1016/j.diabres.2024.111615 · 2024 · External reference
Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine
10.1001/archpsyc.1988.01800330013001 · 1988 · External reference
The positive and negative syndrome scale (PANSS) for schizophrenia
10.1093/schbul/13.2.261 · 1987 · External reference
Presynaptic dopamine capacity in patients with treatment-resistant schizophrenia taking clozapine: an [18F]DOPA PET study
10.1038/npp.2016.258 · 2017 · External reference
The role of peripheral inflammation in clinical outcome and brain imaging abnormalities in psychosis: a systematic review
10.3389/fpsyt.2021.612471 · 2021 · External reference
Constructing the immune signature of schizophrenia for clinical use and research; an integrative review translating descriptives into diagnostics
10.3389/fpsyt.2018.00753 · 2019 · External reference
Establishing the brief assessment of cognition - short form
10.1016/j.jpsychires.2017.05.006 · 2017 · External reference
Immune signatures of treatment-resistant schizophrenia: a FondaMental academic centers of expertise for schizophrenia (FACE-SZ) study
2021 · External reference
Interleukin-6 in aging and chronic disease: a magnificent pathway
10.1093/gerona/61.6.575 · 2006 · External reference
Neuroinflammation in schizophrenia: meta-analysis of in vivo microglial imaging studies
10.1017/s0033291718003057 · 2019 · External reference
Immunoinflammatory and oxidative alterations in subjects with schizophrenia under clozapine: a meta-analysis
10.1016/j.euroneuro.2023.04.003 · 2023 · External reference
Cytokine alterations in schizophrenia
10.3389/fpsyt.2019.00892 · 2019 · External reference
The relationship between inflammatory biomarkers and cognitive dysfunction in patients with schizophrenia: a systematic review and meta-analysis
10.1016/j.pnpbp.2022.110668 · 2023 · External reference
Factors associated with cognitive dysfunction in treatment-responsive and -resistant schizophrenia: a pilot cross-sectional study
10.1016/j.jpsychires.2024.08.012 · 2024 · External reference
Effect of lemborexant on pharmacokinetics of clozapine: a potential drug-drug interaction mediated by time-dependent inhibition of CYP3A4
10.1111/bcp.15889 · 2024 · External reference
An abbreviated version of the brief assessment of cognition in schizophrenia (BACS)
10.4321/s0213-61632015000200004 · 2015 · External reference
Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology
10.1016/s0920-9964(01)00296-1 · 2002 · External reference
Serum interleukin-6 in schizophrenia: a system review and meta-analysis
10.1016/j.cyto.2021.155441 · 2021 · External reference
